8635 W. 3rd St. Suite #485-W
Los Angeles, CA 90048
(310) 652-9162

Alan David Dauer, M.D., F.A.C.P.

Education and Experience

1953-1956

Bachelor of Science, Zoology, University of Michigan

1962

Doctor of Medicine, New York Medical College

1962-1963

Internship, Cedars of Lebanon Hospital (Cedars-Sinai Medical Center)

1963-1965

Residency, Cedars of Lebanon Hospital (Cedar-Sinai Medical Center)

1965-1966

Fellowship in Renal and Respiratory Physiology, Cedars-Sinai Medical Center

1965-1966

Post Doctoral Scholar of NIH Grant, University of California Los Angeles Medical School.

1965-1966

Associate Attending Internal Medicine Supervisor, Nephrology Clinic Cedars- Sinai Medical Center.

1966-1998

Private Practice in Whittier, California-Acquired by Friendly Hills Medical Group in 1991.

1968-1998

Director, Clinical Laboratory Colima Internal Medical Group.

1975-1982

Associate Clinical Professor of Medicine, University of Southern California School of Medicine.

1976-1983

Chief of Medical Staff, Whittier Hospital Medical Center

1976-1983

Chairman of Quality Assurance Committee

1982-1986

Institutional Review Board, Colima Internal Medical Group

1983-1998

Chairman of Ethics Committee of Friendly Hills Regional Medical Group

1993-1998

Clinical Professor of Medicine, University of California School of Medicine, Irvine.

1993-1998

Chairman of the Department of Internal Medicine, Friendly Hills Medical Group

1999

Present Clinical Professor, UCLA Medical School


Appointments

1976-1988

Medical Director, Coronary Care Unit, Whittier Hospital Medical Center

1976-1988

Medical Director, Medical Education, Whittier Hospital Medical Center

1976-1998

Medical Director, Whittier Dialysis Center

1984-present

Active Staff, Cedars-Sinai Towers Artificial Kidney Center

1998-present

Associate Physician, Tower Nephrology Medical Group, Beverly Hills Dialysis, Center, Crescent Heights Dialysis Center


Staff Privileges

1976-1988

Medical Director, Coronary Care Unit, Whittier Hospital Medical Center


Publications

  • Titration of Micro and Ultramico Quantities of Calcium in Blood Serum, Urine and Inorganic Salt Solutions
  • Dauer, Alan D., Iwane C., Marik A., and Smith A., Intensive Coronary Care Training Manual, Compiled for Instructional Use, Whittier Hospital Medical Center, 1971
  • Journal of Respiratory Diseases, Februaru 1984, Book Review Biology in Health and Diseases, p. 94
  • Reviewer for the Journal of Respiratory Diseases, 1982- present
  • Illnesses Possibly Associated with Smoking Clove Cigarettes, Center for Diseases Control Morbidity and Mortality Weekly Report (MMWR), May 31, 1985, Vol. 34, No 21
  • Terazosin: An Effective Once-Daily Monotherapy for the Treatment of Hypertension, Yorke Medical Group, The American Journal of Medicine.
  • EKG of the Month: Digitalis Intoxication vs. Digitalis Need, A94, August 1963, the new Physician
  • American College of Physicians in Support of Fellowship Applications:
  • Prospective in Renal Transplantation, 1983 Non-Hodgkin.s, Lymphoma, 1983 Lupus Nephritis, 1983 Immune Complex Nephritis Folled by Graves. Disease: A Case History, 1983 IGA Nephropathy, 1983.
  • Presentation at the Terazosin Investigators Meeting, Boca Raton, Florida, May 3-5, 1985: Terazosin: An Effective Once-Daily Monotherapy
  • Terazosin: An Effective Once-Daily Monotherapy for the Treatment of, The American Journal of Medicine, May 23, 1986, Vol. 80, and p. 29.
  • Terazosin: An Effective Once-A-Day Antihypertensive Agent With an Apparent Beneficial Effect on Cholesterol, .Today.s Therapeutic Trends. 4(1); 1-15, 1986.
  • Lisinopriol/HCTZ in Essential Hypertension, American Society for Clinical Pharmocology and Therapeutics 1-2, p.64, march 28, 1987
  • Enalapril in the Chronic Treatment of Congestive Heart Failure Patients, submitted to the American College of Cardiology.
  • Presentation at the Innisbrool Resort & Convention Center, Tampa, Florida, June 5-7, 1987, Terazosin: An F=Effective Once-Daily Monotherapy for the Treatment of Hypertension.
  • Serotonergic Appetite Suppression as Treatment of Obesity, Accepted by the International Journal of Obesity, October 11, 1988

Professional Affiliations

  • Fellow, America, College of Physicians
  • Diplomate of the American Board of Internal Medicine
  • American College of Cardiology
  • California Society of Internal Medicine
  • Los Angeles County Medical Association
  • American Society for Clinical Pharmacology and Therapeutics
  • American Society of Hypertension, Inc.
  • American Society of Nephrology

Community Service

  • Past President, Board of Directors, Downey Museum of Art, Downey, California.
  • Past President, Board of Directors, Hebrew Academy, Long Beach, California.
  • Past member, Rio Hondo Liaison committee, Department of Mental health.

Clinical Study Location

  • Tower Nephrology Medical Group, Los Angeles, CA
  • DaVita Beverly Hills, Los Angeles, CA
  • DaVita Crescent Heights, Los Angeles, CA

Clinical Studies

2013 ICH Good Clinical Practice for Clinical Trial Sites (Certificates)

Sub-Investigator 2014 Ferumoxytol for Anemia of CDK Trial (FACT): A Phase IV, open Label, Multicenter Trial, with MRI Substudy, of Repeated Doses Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Definiency Anemia (IDA) in Chronic Kidney Disease (CDK) Patients on Hemodialysis
Sub-Investigator 2014 A Multicenter Single-arm Extention Study to Describe the Long- term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Sub-Investigator 2013 A randomized, Double-blind, Placebo-controlled, Phase 3 Study to assess the Efficacy and Safety of AMG 416 in the Treatment of Seconday Hyperparathroidism in Subjects With Chronic Kidney Disease on Hemodialysis.
Sub-Investigator 2013 ZS-003: “A Phase III multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia.
Sub-Investigator 2013 Randomized, Double-blind, Parallel-group, Multicenter study to evaluate the efficacy and safety of HX575 Epoetin alfa cs. US licensed Epoetin alfa (Epogen/Procrit) in the treatment of anemia associated with chronic kidney disease.
Sub-Investigator 2013 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults With Type 2 Diabetes and Overt Nephropathy Study #B1261007-1137
Sub-Investigator 2012 A phase 2b, Prospective, Double- Blind, Placebo- Controlled, Multicenter to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedence, in Type 2 Diabetic Subjects with Nephropathy
Sub-Investigator 2011 A Three-Period, 58-Week Safety and Effiancy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Sub-Investigator 2011 Bardoxolone Methyl Evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (Beacon)
Sub-Investigator 2011 A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study

 

2010 GCP Certified by the National Cancer Institute

Sub-Investigator 2010

A 30-Week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and Rosuvastatin compared to Rosuvastatin Monotherapy in Dyslipidemic subjects with Stage 3 Chronic Kidney Disease.

Sub-Investigator 2009

A Phase 2a, prospective, randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Atrasentan on reducing albuminuria in type 2 diabetic nephropathy subjects who are currently being treated with an renin-angiotensin system inhibitor.

Sub-Investigator 2008

Phase 2, randomized, double-blind, placebo-controlle, parallel group, fixed dose study of AMG 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia.

Sub-Investigator 2007

A Phase III, Randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin

Sub-Investigator 2007

Outcome trial evaluating the efficacy and safety of Norditropin® on adult patients on chronic haemodialysis

Sub-Investigator 2007

A Phase IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects treated with lanthanum Carbonate (Fosrenol ®)

Sub-Investigator 2007

A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis patients who self inject or receive in-center Injections.

Sub-Investigator 2007

Prospective, Open Label, Randomized multicenter study to demonstrate the efficacy and safety of intravenous (IV) RO0503821 for hemoglobin control in patients transitioning from chronic kidney disease. Stage 4 through dialysis.

Sub-Investigator 2007

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease.

Principal Investigator 2007

A Randomized, Open-Label, multicenter study Epoetin Alfa comparing two extended-dosing regimens, Once-every-Two-Weeks, and Once- Every-Four-Weeks, with the Once-Weekly dosing regimen for maintenance treatment in anemic subjects with chronic kidney disease

Sub-Investigator 2007

An Open Label Randomized, Paralled-Group, Clinical Endpoint Bioequivalence Study of Generic Iron Sucrose Injection USP Versus Venofer® Iron Sucrose Injection USP in Hemodialysis Patients with Iron Deficiency

Sub-Investigator 2006

Arandomized, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2diabetes mellitus and diabetic nephropathy.

Sub-Investigator 2006

Evaluation Of Cinacalcet HCI Therapy to Lower cardio Vascular Events.

Principal Investigator 2006

A Phase III Study if the Safety and Efficacy of Ferumoxytol (compared with oral iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients not on Dialysis.

Sub-Investigator 2005

An Open-Label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects with Chronic Kidney Disease.

Sub-Investigator 2004

Phase IIIb, Multi-Center, Two-Cohort, Randomized Study, with an Open-Label Run-In and a Long-Term Extension Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis.

Sub-Investigator 2004

Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of Staph VAX, a Bivalent Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis.

Principal Investigator 2003

Phase 3 Cinacalcet open label to reach K/DOQI levels

Principal Investigator 2003

Phase 3 trial in treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on Cinacalce.

Sub-Investigator 2003

Phase 4 Prospective, Randomized, double-blind, double-dummy, forced- titration, multicenter, parallel group, one year treatment trial to compare MICARDIS (telmisartan) 80 mg versus COZAAR (losartan) 100mg, in hypertensive type 2 diabetic patients with overt nephropathy (AMADEO Study)

Principal Investigator 2003

Phase 3 Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent When Two Different Vitamin D Regimens are used in Subjects with Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Sub-Investigator 2002

Phase 4 to evaluate subject preference for Aranesp administered administered once monthly, ie every 4 weeks (Q4W) or procrit administered once weekly (QW).

Principal Investigator 2002

Phase 3 Placebo-controlled, Double-blind, Extension Study to Assess the Long-term Safety of an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease.

Sub-Investigator 2002

Phase 4 Disease/Case Management of Patients Receiving ARANESP (darbepoetin alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 4, Multicenter Trial Using Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) and Iron Guided Algorithms to Treat Subjects with Anemia of Chronic Renal Insufficiency (CRI).

Sub-Investigator 2002

Phase 4 Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (darbepoetin alfa) in subjects with Anemia of Chronic Renal Insufficiency (CRI).

Principal Investigator 2002

Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent on Secondary Hyperparathyroidism of End Stage Renal Disease Treated with Hemodialysis.

Principal Investigator 2001

Phase 3 A Multicenter, Open-label Extension Study to Assess the Long- term Safety and Efficacy if an Oral Calcimimetic Agent in Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD).

Principal Investigator 2001

Phase 2 Randomized, double-blind Study to Assess the Efficacy and safety of an Oral Calcimimetic Agent on secondary Hyperparathyroidism of End Stage Renal Disease treated with Hemodialysis.

Principal Investigator 2000

Phase 2 Pharmacokinetic (PK) Analysis of Chronic Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis (HD).

Sub-Investigator 1999

Chronic Renal Insufficiency registry in a prospective, observational study designed to gather data on the use of various interventions delivered to patients with renal insufficiency, pre-ESRD.

Principal Investigator 1999

Randomized Study Comparing the Efficiency of Once Weekly Versus 3 Times Weekly Administration of Subcutaneous (SC) Novel Erythropoiesis Stimulating Protein (NESP) to Subjects with End-Stage Renal Disease (ESRD) Receiving Hemodialysis.

Principal Investigator 1990-1991

E.R. Squibb & Sons: Zofenopril Calcium

Principal Investigator 1989-1991

Burroughs Wellcome Company: Effects of Digoxin Withdrawal on Exercise Tolerance

Principal Investigator 1989-1990

Miles Pharceuticals: Nifedine

Co Investigator 1988-1990

Abbott Laboratories: Clarithromycin for Pneumonia

Principal Investigator 1988-1989

Marion Laboratories: Carizim for Hypertension

Principal Investigator 1988-1989

Merck Sharp & Dohme: Lovastatin (Mevacor)

Principal Investigator 1987-1990

Pfizer Pharmaceuticals: Prazosin GITS

Principal Investigator 1987-1988

Hoechst Roussel Pharmaceuticals Ramipril vs. Enalapril

Principal Investigator 1986-1990

Ortho Pharmaceutical: Erythropoietin

Principal Investigator 1986-1988

Eli Lilly and Company: Nizatidine

Principal Investigator 1986-1988

Smith Kline and French Laboratories: Fenoldopam

Principal Investigator 1986-1987

Merck Sharp & Dohme Laboratories: Felodipine

Principal Investigator 1986-1989

Roche laboratories: Cilazorpril vs. Captopril

Principal Investigator 1986-1987

Merck Sharp & Dohme Laboratories: Aldomet

Principal Investigator 1986-1987

Wallace Laboratories: Soma

Principal Investigator 1986-1987

Ciba-Geigy Corporation: Voltaren

Principal Investigator 1986-1988

Beckitt & Colman Pharmaceuticals: Buprenorphine vs. Morphine

Principal Investigator 1985-1987

Wyeth Laboratories: Dezocine (Open Label)

Principal Investigator 1985-1987

Syntex Laboratories: Ketorolac vs. Acetaminophen & Codeine

Principal Investigator 1985-1986

Eli Lilly & Company Laboratories: Nalfon Sustained Release.

Principal Investigator 1985

Eli Lilly & Company: Fluoxetine

Principal Investigator 1985-1987

Merck Sharp & Dohme Laboratories: Enalapril, first Line therapy

Principal Investigator 1985-1986

Merck Sharp & Dohme Laboratories: Combination Lisinopril And Hydrochlorothiazide

Principal Investigator 1984-1988

Ayerst Laboratories: Ultradol vs. Ibuprofen, Long Term

Principal Investigator 1984-1985

Ayerst Laboratories: Ultradol vs. Piroxican and Placebo.

Principal Investigator 1984-1986

Ayerst laboratories: Betacor vs. Inderal

Principal Investigator 1984-1985

Merck Sharp & Dohme Laboratories: Meduretic vs.

Principal Investigator 1984-1987

Merck Sharp & Dohme Laboratories: Enalapril (Open-Label)

Principal Investigator 1983-1986

Lilly Laboratories: Pinacidil vs. Hydralazine

Principal Investigator 1982-1986

Abbott Laboratories: Terasozin vs. Placebo and Open Long

Principal Investigator 1981-1983

Wyeth Laboratories: Indoramin vs. Prazosin and Hydrochlorothiazide

Principal Investigator 1968

Study of Long-Acting Nitrates on Patients with Coronary and Insufficiency